Reslizumab

Severe Asthma Digital Marketing Trends Report 2022: Assess Key Digital Marketing Metrics Including Branded Websites for Patients and Healthcare Professionals, Mobile Apps, and Social Media Accounts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
Digital Marketing, Managed Care, Communications, Health, Regeneron Pharmaceuticals, Digital, DDA, Social media, AstraZeneca, GSK, SEO, Teva, Asthma, HCP, Genentech, Reslizumab, HCPS, Novartis, Comparison, Patient, Pharmaceutical industry, Online shopping, Omalizumab, Dupilumab, Sanofi

For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK's Nucala.com at approximately $900,000.

Key Points: 
  • For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK's Nucala.com at approximately $900,000.
  • This report assesses key digital marketing metrics of pharma assets in severe asthma, including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts.
  • Understand the digital marketing competitive landscape in severe asthma, with a view of leading patient and HCP branded assets across different regions.
  • See what pharma social media accounts in severe asthma are the most active and achieving the most engagement.

Kinaset Therapeutics Appoints Christopher O’Brien, MD, PhD, FCCP, as Chief Medical Officer

Retrieved on: 
Thursday, July 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, UC, Patient, Teva Pharmaceuticals, Atlas Venture, University, COPD, Molecular biology, Reslizumab, Therapy, Salbutamol, Degenerative disease, Pulmonology, Internal medicine, Company, Atopic dermatitis, College, Atlas, American College of Chest Physicians, Critical Care Medicine (journal), Hospital, Janssen, Shanda, Doctor of Philosophy, University of Connecticut School of Medicine, JAK, Hospital of the University of Pennsylvania, Quality of life, Physician, Medicine, Inflammatory bowel disease, Obstructive lung disease, AstraZeneca, Head, Janssen Pharmaceuticals, Inflammation, Asthma, MD, Life cycle, NDA, Rheumatoid arthritis, Pharmaceutical industry, Ustekinumab, Biology

Kinaset Therapeutics , a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, announced the appointment of Dr. Chris OBrien as the Company's Chief Medical Officer.

Key Points: 
  • Kinaset Therapeutics , a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, announced the appointment of Dr. Chris OBrien as the Company's Chief Medical Officer.
  • "We are thrilled to have Chris join the Kinaset executive team," said Robert Clarke, PhD, Chief Executive Officer of Kinaset.
  • Dr. OBrien stated, Patients with poorly controlled moderate or severe asthma remain underserved by available therapeutics today.
  • Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases.

Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations

Retrieved on: 
Tuesday, January 4, 2022
Growth, TEL, Private Securities Litigation Reform Act, Rosemont College, Communication, Doctor of Philosophy, Forward-looking statement, Inflammation, Nature, SEC, Therapy, CMC, Research, Marketing, Patient, Drug development, Cirrhosis, CMMB, Fibrosis, Armodafinil, Reslizumab, Bachelor of Science in Human Biology, Data management, CCL24, Risk, Primary sclerosing cholangitis, Pharmaceutical industry, Cephalon, ViroPharma, Teva, Modafinil

(Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today named Jack Lawler Vice President of Global Clinical Development Operations.

Key Points: 
  • (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today named Jack Lawler Vice President of Global Clinical Development Operations.
  • "We are delighted to welcome Jack to Chemomab, with his more than two decades of experience in clinical development planning, operations and management, spanning pre-IND activities through CMC and regulatory," said Dale Pfost, PhD, Chief Executive Officer of Chemomab.
  • "We look forward to his contributions as we build out our U.S.-based clinical development team that complements our existing clinical expertise in Israel."
  • Prior to joining Chemomab, Mr. Lawler served on the senior leadership team at Goldfinch Bio as Vice President, Clinical Operations and Data Management.

Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Retrieved on: 
Monday, May 17, 2021
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Drugs, Branches of biology, Medical specialties, Dexpramipexole, Thiazoles, Asthma, Eosinophil, Paracetamol, Reslizumab

b'Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma.

Key Points: 
  • b'Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma.
  • The data were presented in a virtual poster session at the ATS 2021 International Conference.\nThe EXHALE trial was a randomized, double-blind, placebo-controlled study of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) \xe2\x89\xa5300/\xc2\xb5L.
  • Dexpramipexole study drug at oral doses of 75 mg/day, 150 mg/day, or 300 mg/day was added to standard of care.
  • Eosinophils, a type of white-blood cell, are validated as a therapeutic target in asthma as evidenced by the regulatory approval of multiple eosinophil-lowering biologics.

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Retrieved on: 
Thursday, January 14, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Medical specialties, Clinical medicine, Respiratory therapy, Medicine, Dexpramipexole, Thiazoles, Asthma, Monoclonal antibodies, Reslizumab

Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma.

Key Points: 
  • Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma.
  • In the EXHALE trial, eosinophil depletion in blood by oral dexpramipexole correlated with clinically important improvement in lung function as measured by pre-bronchodilator FEV1.
  • These Phase 2 results strongly support the continued development of dexpramipexole as a potential first-in-class oral agent for the treatment of eosinophilic asthma, said Michael Bozik, M.D., President and CEO of Knopp.
  • Knopps clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma.

DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma

Retrieved on: 
Tuesday, November 17, 2020
Interleukins, Branches of biology, Medical specialties, Clinical medicine, Asthma Canada, Asthma, Dupilumab, Interleukin 4, Interleukin-1 family, Interleukin 13, Reslizumab, Occupational asthma

DUPIXENT is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins3and is not an immunosuppressant.

Key Points: 
  • DUPIXENT is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins3and is not an immunosuppressant.
  • "The daily management of asthma can be a significant burden for Canadians living with the disease.
  • It can be even more frustrating for those patients who are compliant with their Asthma Action Plan and medication, but their debilitating symptoms persist," says Vanessa Foran, President & CEO, Asthma Canada.
  • Severe Asthma.

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

Retrieved on: 
Tuesday, October 13, 2020
Monoclonal antibodies, Respiratory therapy, Health, Clinical medicine, Medical specialties, Asthma, Dupilumab, Reslizumab

Dupixent is the only biologic shown in a controlled Phase 3 trial to improve lung function in children, which is generally consistent with results seen in the adolescent and adult trials.

Key Points: 
  • Dupixent is the only biologic shown in a controlled Phase 3 trial to improve lung function in children, which is generally consistent with results seen in the adolescent and adult trials.
  • These positive data are especially encouraging for younger children who are struggling to manage their uncontrolled asthma.
  • In the U.S., there are approximately 75,000 children 6-11 years old with uncontrolled moderate-to-severe asthma, and many more of these children worldwide.
  • These impressive Phase 3 data in children with asthma show Dupixent significantly reduced annual severe asthma attacks and also improved lung function consistently across patients with markers of type 2 inflammation.

Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

Retrieved on: 
Wednesday, September 16, 2020
Health, Branches of biology, Dexpramipexole, Thiazoles, Monoclonal antibodies, Asthma, Clinical trial, Eosinophil, Reslizumab

PITTSBURGH, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Knopp Biosciences LLC today announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with moderate-to-severe eosinophilic asthma.

Key Points: 
  • PITTSBURGH, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Knopp Biosciences LLC today announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with moderate-to-severe eosinophilic asthma.
  • Knopp is committed to developing oral dexpramipexole as a targeted, eosinophil-depleting, pre-biologic treatment for patients with moderate-to-severe eosinophilic asthma.
  • Knopp has previously reported the highly significant eosinophil-lowering effects of oral dexpramipexole in clinical trials, including in a Phase 2 clinical trial in HES .
  • Knopps clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma.

Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma

Retrieved on: 
Tuesday, September 8, 2020
Respiratory therapy, Health, Monoclonal antibodies, Clinical medicine, Chronic lower respiratory diseases, Asthma, Dupilumab, Reslizumab, Brittle asthma

Data from the trial will be presented during a live session at the virtual 2020 European Respiratory Society (ERS) International Congress.

Key Points: 
  • Data from the trial will be presented during a live session at the virtual 2020 European Respiratory Society (ERS) International Congress.
  • These data suggest Dupixent may slow the progressive decline in lung function that many patients with moderate-to-severe asthma experience, as shown by the sustained improvement in lung function for up to three years.
  • Asthma attacks: Patients maintained a low rate of severe asthma attacks (unadjusted annualized severe exacerbation rate) with an average of 0.31-0.35 events per year.
  • In the year prior to commencing Dupixent trials, the rate of severe asthma attacks was 2.09-2.17 events per year.

AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Same

Retrieved on: 
Tuesday, August 11, 2020
Managed care, Other Health, General Health, Entertainment, Film & Motion Pictures, Pharmaceutical, Books, Oncology, General Entertainment, TV and Radio, Cardiology, Biotechnology, Health, Medical specialties, Branches of biology, Clinical medicine, Asthma, Respiratory therapy, Immune system disorders, Eosinophil, Eosinophilic myocarditis, Reslizumab, Eosinophilic Asthma, AstraZeneca

Visit www.easthma.com to sign up for a free blood test and learn more information about eosinophilic asthma.

Key Points: 
  • Visit www.easthma.com to sign up for a free blood test and learn more information about eosinophilic asthma.
  • *Although not defined by clinical guidelines, eosinophilic asthma was considered an eosinophil count of 150 cells/L or more for this CDC survey analysis.
  • To learn more about eosinophilic asthma and to sign up for a free blood test, visit www.easthma.com .
  • Asthma.